ライフサイエンスコーパス: transcriptase

1 hain reaction using human telomerase reverse transcriptase.

2 ded in elongation by murine leukemia reverse transcriptase.

3 l diversity-generating system with a reverse transcriptase.

4 the RNA template of human telomerase reverse transcriptase.

5 and temperatures and apply it to HIV reverse transcriptase.

6 using a thermostable group II intron reverse transcriptase.

7 quence derived from human telomerase reverse transcriptase.

8 an DNA polymerases relative to viral reverse transcriptases.

9 mRNA expression of human telomerase reverse transcriptase, a catalytic subunit of telomerase that wa

10 nto the regulatory interplay between reverse transcriptase, A3G and cellular DNA repair machinery, an

11 ated Tbk1 and, importantly, blocking reverse transcriptase activity suppressed the expression of inte

12 also be capable of functioning as a reverse transcriptase, an activity that has never been demonstra

13 Quantitative reverse transcriptase analysis demonstrated a 2-fold increase in

14 itis B virus (HBV) quasispecies with reverse transcriptase and HBV surface antigen (HBsAg) heterogene

15 branch site emerges between the Prp8 reverse transcriptase and linker domains and extends towards the

16 ced fit in enzyme specificity of HIV reverse transcriptase and many other enzymes.

17 A targets using polymerase with both reverse-transcriptase and strand displacement activities to obta

18 1.3-kb fragment of p6, protease, and reverse transcriptase) and the levels of HIV RNA in single HIV-i

19 iency virus type 1 (HIV-1) protease, reverse transcriptase, and integrase sequences-three genes that

20 RNA dependent DNA-polymerases, reverse transcriptases, are key enzymes for retroviruses and ret

21 ound that (th)A is recognized by AMV reverse transcriptase as A, and is deaminated rapidly by human A

22 eases the rate of both human and HIV reverse transcriptase-associated RNase H-mediated cleavage of th

23 rameshifting, is shown here to limit reverse transcriptase base substitution and indel 'errors' in th

24 ped a high-throughput variant of the reverse-transcriptase-based method for identifying 2'-O-methyl m

25 and is dependent on the DGR-encoded reverse transcriptase (bRT) and accessory variability determinan

26 nd identify the suppression of HIV-1 reverse transcriptase by a directly interacting host protein as

27 d G-rich sequences, ahead of diverse reverse transcriptases can be strong stimulators for slippage at

28 omain" (IFD) in the human telomerase reverse transcriptase catalytic subunit (hTERT) have previously

29 disorder." RMRP binds the telomerase reverse transcriptase (catalytic subunit) in some cell lines, ra

30 Reverse transcriptase-catalyzed reverse transcription critically

31 ere no fixed mutations in the Gag or reverse transcriptase coding sequence.

32 rgest component of the coronavirus replicase-transcriptase complex, nsp3, contains multiple modules,

33 activation of fibroblast telomerase reverse transcriptase-dependent proliferation, motility, and ind

34 sults revealed three interconverting reverse transcriptase-DNA/RNA species; 43% were active for both

35 Mutation V111I in the HIV-2 reverse transcriptase enzyme was identified in patients failing

36 in the RNA were not detected by the reverse transcriptase enzyme.

37 ibutor to HIV-1 genetic variation is reverse transcriptase errors.

38 igation probes than methods that use reverse transcriptase for cDNA synthesis of miRNA.

39 ganization of the t/PK on telomerase reverse transcriptase for medaka and human is modeled based on t

40 al fusion proteins of the telomerase reverse transcriptase from its endogenous locus.

41 as well as the spatial separation of reverse transcriptase from the viral genome during early steps o

42 t expression of the human telomerase reverse transcriptase gene (hTERT).

43 how that at the same shift motif HIV reverse transcriptase generates -1 and +1 indels with their rati

44 we demonstrate that human telomerase reverse transcriptase (hTERT) activates vascular epithelial grow

45 ptides derived from human telomerase reverse transcriptase (hTERT) and referred as universal cancer p

46 The human telomerase reverse transcriptase (hTERT) gene is repressed in most somatic

47 l activation of the human telomerase reverse transcriptase (hTERT) gene, which remains repressed in a

48 the promoter of the human telomerase reverse transcriptase (hTERT) gene.

49 Human telomerase reverse transcriptase (hTERT) is overexpressed in cancer cells a

50 Human telomerase reverse transcriptase (hTERT) plays a key role in tumor invasion

51 unit of telomerase, human telomerase reverse transcriptase (hTERT), is overexpressed in approximately

52 endent and simultaneous discovery of reverse transcriptase in retroviruses (then RNA tumor viruses) b

53 ately was proven by his discovery of reverse transcriptase in Rous sarcoma virus virions.

54 ) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and lipopolys

55 h POT1/TRF2 and via human telomerase reverse transcriptase inhibition through JNK activation.

56 region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site.

57 n the presence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) showed s

58 ns (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and pro

59 ir+lamivudine) with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or 3 NRTIs as long-term

60 nts failing an initial nonnucleoside reverse-transcriptase inhibitor (NNRTI) regimen in Africa and As

61 reasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people ini

62 y virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are

63 ) resistance, 9.8% had nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, and 4.2% had

64 actors associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance.

65 ble to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance.

66 xposure to nonstandard nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based (hazard ratio, 7.1

67 se inhibitor (PI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens with a ba

68 emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz)

69 ate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbone.

70 1 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-v

71 nt indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followe

72 als; 15.8% had nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance, 9.8% had nonn

73 Treatment with the reverse transcriptase inhibitor 3TC resulted in decreased TE tra

74 ed darunavir regimen with nucleoside reverse transcriptase inhibitor background treatment for HIV-1-i

75 ation of LysRS, but treatment with a reverse transcriptase inhibitor does not, suggesting that the tr

76 No individual ARV in the reverse transcriptase inhibitor drug classes was associated with

77 older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identified in sub

78 analyzed whether abacavir, an HIV-1 reverse transcriptase inhibitor often inducing severe delayed-ty

79 rst-line regimen of a non-nucleoside reverse transcriptase inhibitor plus two NtRTIs.

80 with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detect

81 alafenamide delivers the nucleotide reverse transcriptase inhibitor tenofovir to target cells more e

82 RT) containing the modern nucleoside reverse transcriptase inhibitor tenofovir.

83 mong those with mono/dual nucleoside reverse transcriptase inhibitor therapy prior to combination ant

84 g dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the age

85 roportions of overall and nucleoside reverse transcriptase inhibitor-associated minority variant resi

86 the atazanavir group had nucleoside reverse transcriptase inhibitor-associated resistance that led t

87 rval [CI], 90%-99.7%); nonnucleoside reverse transcriptase inhibitor-based, 100% (95% CI, 91%-100%);

88 4 counts and to receive 2 nucleoside reverse transcriptase inhibitors (2NRTI, mainly abacavir+lamivud

89 NRTIs (5.4%), followed by nucleoside reverse transcriptase inhibitors (3.0%) and protease inhibitors

90 imens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or ritonavir-boosted Prot

91 New non-nucleoside reverse transcriptase inhibitors (NNRTI), which are similar in s

92 the impact of several non-nucleoside reverse transcriptase inhibitors (NNRTI; Efavirenz, Etravirine,

93 inhibitors (NRTIs), 4 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 2 protease inhibit

94 rapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromise HIV c

95 ence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (95% CI: 2

96 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) that target the viral

97 a clinical candidate non-nucleoside reverse transcriptase inhibitors (NNRTIs) with a novel aryl-phos

98 riven by resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs).

99 ed with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended as firs

100 Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the essential compo

101 tric trials have compared nucleoside reverse-transcriptase inhibitors (NRTIs) in first-line antiretro

102 ted to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy

103 s for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase stran

104 otease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination

105 Nucleoside reverse transcriptase inhibitors (NRTIs) with L-stereochemistry

106 -1 inhibitors including 6 nucleoside reverse-transcriptase inhibitors (NRTIs), 4 non-nucleoside rever

107 ibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs).

108 e efficacy of commercially available reverse transcriptase inhibitors (RTIs) at inhibiting the enzyma

109 be a major substrate for TREX1, and reverse transcriptase inhibitors (RTIs) were proposed as a thera

110 t cells, such as entry inhibitors or reverse transcriptase inhibitors (RTIs), are ideal candidates fo

111 cART regimen, in favor of nucleoside reverse transcriptase inhibitors and integrase inhibitors (witho

112 2 in 10 patients included nucleoside reverse transcriptase inhibitors associated with darunavir/riton

113 enofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine, rito

114 We further show that the addition of reverse transcriptase inhibitors effectively suppresses the leve

115 teasome inhibitors and nonnucleotide reverse transcriptase inhibitors in the cART regimen, in favor o

116 ctive regimens include nonnucleoside reverse transcriptase inhibitors or boosted protease inhibitors

117 line regimens based on nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.

118 In this model, reverse-transcriptase inhibitors rescued the neurotoxicity of AG

119 bitors, nonnucleoside and nucleotide reverse transcriptase inhibitors TDR mutations, namely, L90M, K1

120 with other non-allergenic nucleoside reverse transcriptase inhibitors, identifying abacavir as a spec

121 y, 1 of which was without nucleoside reverse transcriptase inhibitors, infants had a specific follow-

122 R quantification and the addition of reverse transcriptase inhibitors, is crucial to fully elucidate

123 nce to 1 or more NNRTI or nucleoside reverse transcriptase inhibitors, respectively.

124 troviral therapy with two nucleoside reverse transcriptase inhibitors.

125 with the same backbone of Nucleoside Reverse Transcriptase Inhibitors.

126 The template for telomerase reverse transcriptase is within the RNA subunit of the ribonucle

127 the specific interaction of A3G with reverse transcriptase itself.

128 Subsequent studies of reverse transcriptase led to the elucidation of the mechanism of

129 This assay is based on reverse transcriptase loop-mediated isothermal amplification (RT

130 arge A3G oligomers could block HIV-1 reverse transcriptase-mediated DNA synthesis, thereby inhibiting

131 catalytic-inactive dimers that block reverse transcriptase-mediated DNA synthesis.

132 s on telomeric repeat synthesis by a reverse transcriptase named telomerase.

133 (both groups), eight (13%) of 64 for reverse transcriptase (NtRTI group) and 16 (20%) of 79 for integ

134 binding between the protein subunit reverse transcriptase of the telomerase and its nucleic acid sub

135 virus (HBV) encodes a multifunction reverse transcriptase or polymerase (P), which is composed of se

136 the pregenomic RNA (pgRNA) and viral reverse transcriptase (P).

137 xpression changes using quantitative reverse-transcriptase PCR (qRT-PCR), immunofluorescence, and Lum

138 RACE) for HIV-1 RNA and quantitative reverse transcriptase PCR (qRT-PCR).

139 , and the vaccine-specific real-time reverse transcriptase PCR (rRT-PCR) assay described by F.

140 d and validated a one-step multiplex reverse transcriptase PCR (RT-PCR) to simultaneously detect, qua

141 The assays were evaluated with reverse transcriptase PCR (RT-PCR) using 411 nasopharyngeal swab

142 One-step reverse transcriptase PCR (RT-PCR) was performed in picoliter dr

143 (ddPCR), and real-time quantitative reverse transcriptase PCR (RT-qPCR) from nine human cell lines a

144 Results from quantitative reverse transcriptase PCR analysis clearly demonstrated that, du

145 for the presence of SVA by real-time reverse transcriptase PCR and virus isolation.

146 Reverse transcriptase PCR demonstrated minor intron retention in

147 On admission, reverse transcriptase PCR identified Ebola virus RNA at a higher

148 tion was carried out by quantitative reverse transcriptase PCR in 2 different set of samples.

149 This was confirmed by quantitative reverse transcriptase PCR in infected and uninfected gastric muc

150 miRNAs was confirmed by quantitative reverse transcriptase PCR in samples from set 1 and set 2, respe

151 Reverse transcriptase PCR showed that fruRBA formed an operon wh

152 ng immunofluorescence, western blot, reverse-transcriptase PCR, chromatin immunoprecipitation and pro

153 vels from tissues are measured using reverse transcriptase PCR, microarray analysis or high-throughpu

154 ) detection of T. pallidum in CSF by reverse transcriptase PCR, or (iii) new vision loss or hearing l

155 Using reverse transcriptase PCR, we showed that ORF011 and ORF012 are

156 methods, including culture, EIA, and reverse-transcriptase PCR.

157 e and analyzed histologically and by reverse transcriptase PCR; leukocytes were isolated, stimulated,

158 se requirements limit the utility of reverse transcriptase-PCR methods for rapid diagnostics.

159 Using microarrays, reverse transcriptase-PCR, and immunohistochemistry, their resul

160 ome analysis, quantitative real-time reverse-transcriptase-PCR, and quantitative immunohistochemistry

161 adder cancer (NMIBC) by quantitative reverse transcriptase-PCR.

162 HIV reverse transcriptase plays a central role in viral replication

163 In training, using reverse-transcriptase polymerase chain reaction (PCR), we compar

164 tors was analyzed using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in col

165 cytokeratin (AE1/AE3) and real-time reverse transcriptase polymerase chain reaction (RT-PCR) for car

166 istry underwent molecular staging by reverse transcriptase polymerase chain reaction (RT-PCR).

167 Reverse-transcriptase polymerase chain reaction and immunoblot a

168 s assessed in tumors by quantitative reverse-transcriptase polymerase chain reaction and immunohistoc

169 BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay confirmed

170 breast cancer tumors, a quantitative reverse transcriptase polymerase chain reaction assay was develo

171 monitored in plasma using real-time reverse-transcriptase polymerase chain reaction assays.

172 that a virus detected with real-time reverse-transcriptase polymerase chain reaction in patients with

173 e genes was explored by quantitative reverse transcriptase polymerase chain reaction in rat prefronta

174 cted in cerebrospinal fluid (CSF) by reverse-transcriptase polymerase chain reaction of 16S ribosomal

175 Among the remaining patients, using reverse transcriptase polymerase chain reaction or transcriptome

176 oviding results in <30 minutes) with reverse transcriptase polymerase chain reaction reference standa

177 -assisted microdissection and nested reverse transcriptase polymerase chain reaction were performed.

178 ne profiling (quantitative real-time reverse-transcriptase polymerase chain reaction).

179 ls of the receptor were evaluated by reverse transcriptase polymerase chain reaction, and infection e

180 ated mice were used for quantitative reverse-transcriptase polymerase chain reaction, immunocytochemi

181 easurements: The primary outcome was reverse transcriptase polymerase chain reaction-confirmed influe

182 miRNAs were verified by quantitative reverse transcriptase polymerase chain reaction.

183 ted for verification by quantitative reverse transcriptase polymerase chain reaction.

184 asymptomatic controls with real-time reverse-transcriptase polymerase chain reaction.

185 s were studied by flow cytometry and reverse-transcriptase polymerase chain reaction.

186 he relative vaccine efficacy against reverse-transcriptase polymerase-chain-reaction (RT-PCR)-confirm

187 sults were validated by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and Wes

188 were tested for ZIKV using real-time reverse-transcriptase-polymerase chain reaction and an IgM antib

189 tion showed PRKCA rearrangement, and reverse transcriptase-polymerase chain reaction confirmed the pr

190 Both PLP1 antibody staining and reverse transcriptase-polymerase chain reaction for plp1 mRNA sh

191 were validated by using quantitative reverse transcriptase-polymerase chain reaction in 350 subjects

192 able transcriptomic data followed by reverse transcriptase-polymerase chain reaction suggested that P

193 was also quantified by quantitative reverse transcriptase-polymerase chain reaction, and DNA methyla

194 rimental COPD models by quantitative reverse transcriptase-polymerase chain reaction, immunoblotting,

195 control subjects using quantitative reverse transcriptase-polymerase chain reaction, immunohistochem

196 ofluorescence, Western blotting, and reverse transcriptase-polymerase chain reaction, respectively.

197 By reverse transcriptase-polymerase chain reaction, we confirmed th

198 Quantitative reverse transcriptase-polymerase chain reaction, Western blot, a

199 histology, Western blot, ELISA, and reverse transcriptase-polymerase chain reaction.

200 en) in whom ZIKV RNA was detected on reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay i

201 re tested by means of a quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay w

202 s found in the fetal brain tissue on reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay,

203 2485 (4%) were confirmed by means of reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay.

204 We performed reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays

205 al protein 1 antigen immunoassay and reverse-transcriptase-polymerase-chain-reaction assays.

206 lood and urine specimens for ZIKV by reverse-transcriptase-polymerase-chain-reaction assays.

207 s and, through endogenous transposon reverse transcriptases, produce virus-derived complementary DNAs

208 d function of the retroviral enzymes-reverse transcriptase, protease, and integrase-and have had the

209 ins resistant to drugs targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5

210 resentative sequence variants of the reverse transcriptase protein (RT) of hepatitis B virus (HBV), s

211 s were quantified and compared using reverse-transcriptase qPCR.

212 onidase (GUS) activity, quantitative reverse transcriptase (qRT)-PCR, zymography, and chromatin immun

213 luated in all specimens collected by reverse transcriptase quantitative PCR (RT-qPCR) targeting a con

214 sed by faecal shedding of Sabin 2 by reverse transcriptase quantitative PCR (RT-qPCR).

215 s and chromatin immunoprecipitation, reverse transcriptase quantitative PCR and western blotting anal

216 ling using high throughput stem-loop reverse-transcriptase quantitative polymerase chain reaction and

217 218-5p (miR-218-5p) was validated by reverse-transcriptase quantitative polymerase chain reaction in

218 erived leukocytes were determined by reverse transcriptase quantitative polymerase chain reaction, an

219 re compared using flow cytometry and reverse-transcriptase quantitative polymerase chain reaction.

220 We used a reverse-transcriptase quantitative polymerase-chain-reaction ass

221 ma using high-throughput, stem-loop, reverse transcriptase quantitative real-time PCR miRNA expressio

222 d by using in situ hybridization and reverse transcriptase quantitative real-time PCR.

223 ity to detect several viral mRNAs by reverse transcriptase-quantitative PCR, no production of infecti

224 ns, and in healthy skin specimens by reverse transcriptase-quantitative polymerase chain reaction (RT

225 Single-cell multiplex reverse transcriptase-quantitative polymerase chain reaction (RT

226 ns were assessed in ileal tissues by reverse transcriptase-quantitative polymerase chain reaction.

227 ly degraded in target cells, whereas reverse transcriptase remains active and stably associated with

228 es are prematurely degraded, whereas reverse transcriptase remains active and stably associated withi

229 Telomerase is the essential reverse transcriptase required for linear chromosome maintenance

230 crystallographic studies with HIV-1 reverse transcriptase revealed that alpha-CNPs mimic the dNTP bi

231 The reverse transcriptase ribozyme can incorporate all four dNTPs an

232 s are catalyzed by the HIV-1 enzymes reverse transcriptase (RT) and integrase (IN), respectively.

233 n are catalyzed by the viral enzymes reverse transcriptase (RT) and integrase (IN), respectively.

234 e single molecule level, using HIV-1 reverse transcriptase (RT) as a model system.

235 Targeting the clinically unvalidated reverse transcriptase (RT) associated ribonuclease H (RNase H) f

236 Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) r

237 al analogues also potently inhibited reverse transcriptase (RT) associated RNase H, implying potentia

238 Reverse transcriptase (RT) derived base substitution mutations w

239 otein contains endonuclease (EN) and reverse transcriptase (RT) domains that are necessary for the re

240 Most reverse transcriptase (RT) enzymes belong to a single protein fa

241 RNA aptamers that bind HIV-1 reverse transcriptase (RT) inhibit HIV-1 replication, but little

242 iven by an increase in nonnucleoside reverse-transcriptase (RT) inhibitor (NNRTI) resistance mutation

243 cal benefits of HIV-1 non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are hindered by t

244 Nucleoside reverse transcriptase (RT) inhibitors (NRTIs) are the backbone o

245 Some mutations result because reverse transcriptase (RT) lacks 3' to 5' proofreading exonuclea

246 K65K and K66K mutations in the HIV-1 reverse transcriptase (RT) occur in over 35% of drug-experienced

247 Reverse transcriptase (RT) of human immunodeficiency virus-1 (HI

248 Retroviral reverse transcriptase (RT) of Moloney murine leukemia virus (MoM

249 Formation of the mature HIV-1 reverse transcriptase (RT) p66/p51 heterodimer requires subunit-

250 HIV-1 reverse transcriptase (RT) possesses both DNA polymerase activit

251 Deep sequencing of HIV reverse transcriptase (RT) was performed (Roche/454), and the se

252 hrough a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and huma

253 HIV-1 protease (PR), reverse transcriptase (RT), and integrase (IN) variability prese

254 Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RNase H) r

255 ctor containing an RNase H-deficient reverse transcriptase (RT).

256 ystems, Cas1 is naturally fused to a reverse transcriptase (RT).

257 pe datasets of HIV protease (PR) and reverse transcriptase (RT).

258 oviral (HAART) therapy targeting HIV reverse transcriptase (RT).

259 he essential viral polymerase, HIV-1 reverse transcriptase (RT).

260 eficiency virus (SIV) carrying HIV-1 reverse transcriptase (RT-SHIV), compared to uninfected macaques

261 Bacterial group II intron reverse transcriptases (RTs) function in both intron mobility an

262 Protease and reverse transcriptase sequences from 876 new HIV diagnoses (Apri

263 ed non-B HIV-1 gag and pol (protease/reverse-transcriptase) sequences from Cameroonians for drug resi

264 s using thermostable group II intron reverse transcriptase sequencing (TGIRT-seq) to characterize the

265 ions of branch site are imprecise as reverse transcriptase skips several nucleotides while traversing

266 ing method that couples rG4-mediated reverse transcriptase stalling with next-generation sequencing.

267 e the gene coding for the telomerase reverse transcriptase subunit PpTERT in P. patens, for which onl

268 The reverse transcriptase telomerase adds telomeric repeats to chrom

269 g mutations in the ribonucleoprotein reverse transcriptase, telomerase, are associated with the bone

270 previously classified as products of reverse transcriptase template switching are both enriched in pl

271 chromosomal ends and consists of the reverse transcriptase TERT and the RNA subunit TERC.

272 s using an active site in telomerase reverse transcriptase (TERT) and an integral RNA subunit templat

273 y comprises the catalytic telomerase reverse transcriptase (TERT) and telomerase RNA (TR) that provid

274 romosomes, using a unique telomerase reverse transcriptase (TERT) and template in the telomerase RNA

275 telomere-related genes including the reverse transcriptase (TERT) and the RNA component (TERC) of the

276 Reactivation of telomerase reverse transcriptase (TERT) expression is found in more than 85

277 ma DNA confirmed that the telomerase reverse transcriptase (TERT) gene promoter is a common ALV integ

278 letion in intron 3 of the telomerase reverse transcriptase (TERT) gene that predisposes to CH (rs3400

279 ifferential regulation of telomerase reverse transcriptase (TERT) genes contribute to distinct aging

280 of promoter mutations in telomerase reverse transcriptase (TERT) in blood leukocytes of approximatel

281 ucleotide variants in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogena

282 riptional reactivation of telomerase reverse transcriptase (TERT) reconstitutes telomerase activity i

283 ally, SVs were confirmed in telomere reverse transcriptase (TERT) upstream regions in several cancers

284 ts, the catalytic subunit telomerase reverse transcriptase (TERT) uses the RNA subunit (TER) as a tem

285 associated genes IGF2 and telomerase reverse transcriptase (TERT) were overexpressed in fibroblasts f

286 tions in the promoter for telomerase reverse transcriptase (TERT), along with BRAF alterations, has r

287 mere length-1 (RTEL1) and telomerase reverse transcriptase (TERT), genes involved in telomere regulat

288 th only binding sites for telomerase reverse transcriptase (TERT), minimized hTR assembled biological

289 ulated growth may express telomerase reverse transcriptase (TERT), the dual function of which consist

290 35 cancers, 73% expressed telomerase reverse transcriptase (TERT), which was associated with TERT poi

291 telomerase RNA (TER) and telomerase reverse transcriptase (TERT).

292 vity of thermostable group II intron reverse transcriptases (TGIRTs) for DNA-seq library construction

293 otein complex that includes a unique reverse transcriptase that catalyzes the addition of single-stra

294 tability or expression of telomerase reverse transcriptase, these rare genetic disorders are associat

295 rages the DNA polymerase activity of reverse transcriptase to simultaneously perform proximity extens

296 in vivo chemical modifications uses reverse transcriptase truncation products, which introduce biase

297 l length of protease and part of the reverse transcriptase was packaged into a modified lentivirus ca

298 recombinant AREG induced telomerase reverse transcriptase, which appeared to be essential for the pr

299 sses viral replication by inhibiting reverse transcriptase, which may restore the HBV-specific adapti

300 HTBS recruits HIV reverse transcriptase, which nucleates DNA synthesis and is aide